Kidney Disease News and Research RSS Feed - Kidney Disease News and Research

Breakthrough in fight against rare kidney disease - Membranous Nephropathy

Breakthrough in fight against rare kidney disease - Membranous Nephropathy

Scientists at The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust have made a significant breakthrough in the fight against Membranous Nephropathy (MN) - a rare kidney disease which can lead to kidney failure. [More]
Sheffield scientists to showcase novel medical discoveries during International Clinical Trials Day

Sheffield scientists to showcase novel medical discoveries during International Clinical Trials Day

WORLD-leading researchers and scientists from Sheffield Teaching Hospitals Foundation Trust and the University of Sheffield will be giving people in Sheffield and beyond a unique insight into how they can contribute to groundbreaking medical discoveries during International Clinical Trials Day (Wednesday 20 May 2015). [More]
Wearable diagnostic machines presented at Elsevier's 4th International Conference on Bio-Sensing Technology

Wearable diagnostic machines presented at Elsevier's 4th International Conference on Bio-Sensing Technology

Wearable E-skin that can measure heart rate and blood pressure, and paper diagnostic machines the size of a credit card that can give instant readings on blood and saliva samples are two new bio-sensing technologies presented at Elsevier's 4th International Conference on Bio-Sensing Technology in Lisbon, Portugal on 12 May 2015. [More]
New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

New Johns Hopkins-led research suggests risk factors for developing acute kidney injury

Physicians treating hospitalized patients for conditions unrelated to the kidneys should pay close attention to common blood and urine tests for kidney function in order to prevent incidental injury to the organs that help cleanse the body of toxins, new Johns Hopkins Bloomberg School of Public Health-led research suggests. [More]
Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics reports positive results from PT20 trial in people with hyperphosphataemia

Phosphate Therapeutics Limited, a development-stage specialty pharmaceuticals company, today announces positive results from the PEACH pivotal study of PT20 in subjects with hyperphosphataemia related to dialysis dependent chronic kidney disease (DD-CKD). [More]
Bone-marrow-derived MSCs can promote fracture healing

Bone-marrow-derived MSCs can promote fracture healing

Mesenchymal stem cells (MSCs) have been transplanted to successfully treat a variety of diseases and conditions. The benefit of using MSCs is their ability to self-renew and differentiate into a variety of specialized cell types, such as osteoblasts (cells contributing to bone formation), chondrocytes (cartilage cells), adipocytes (fat cells), myocardiocytes (the muscle cells that make up the cardiac muscle), and neurons (nervous system cells). [More]
New genetic mutation appears to protect people from Type 2 diabetes

New genetic mutation appears to protect people from Type 2 diabetes

An international team of scientists led by a Cedars-Sinai researcher has identified a new genetic mutation that appears to protect people from developing Type 2 diabetes. [More]
Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories"). [More]
Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration. [More]
AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular. [More]
Study shows NASH linked to 50% higher death rates compared with NAFLD

Study shows NASH linked to 50% higher death rates compared with NAFLD

Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD). [More]

First CE marked FGF23 ELISA assay launched at Biomedica Immunoassays

The biomarker specialists at Biomedica Immunoassays, announced the launch of the first CE marked FGF23 (C-terminal) ELISA assay which specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. The FGF23 ELISA assay complements the existing Biomedica assays directed against chronic kidney disease - mineral and bone disorder (CKD-MBD) in a growing collection. [More]
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

CTI BioPharma Corp. and Baxter International Inc. today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill). [More]
Manchester scientists make key finding that could help deliver early test for kidney disease

Manchester scientists make key finding that could help deliver early test for kidney disease

Scientists at The University of Manchester have made an important finding that could help develop an early test for kidney disease. [More]
New CUMC study finds DNA anomalies in kids with chronic kidney disease

New CUMC study finds DNA anomalies in kids with chronic kidney disease

A significant proportion of children with chronic kidney disease (CKD) have unsuspected chromosomal imbalances, including DNA anomalies that have been linked to neurocognitive disorders, according to a new Columbia University Medical Center study. [More]
New UM SOM study reveals why thiazide drugs not effective in some patients

New UM SOM study reveals why thiazide drugs not effective in some patients

Every year, more than 120 million prescriptions are written worldwide for thiazide drugs, a group of salt-lowering medicines used to treat high blood pressure. These drugs are often work very well, and over decades have saved hundreds of thousands of lives. [More]
MGH researchers find probable mechanism associated with risk of developing serious diseases

MGH researchers find probable mechanism associated with risk of developing serious diseases

Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications. In a paper published in the American Journal of Hematology, the research team reports finding that higher levels of a measure routinely taken as part of the complete blood count - the extent of variation in the size of red blood cells - is caused by reduced clearance of aging cells from the bloodstream. [More]
Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A. [More]
Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Managing autosomal dominant polycystic kidney disease: an interview with Dr Richard Sandford, University of Cambridge

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases. It's also one of the most common reasons that people require dialysis or transplantation... [More]
DFG selects 10 researchers to receive 2015 Heinz Maier-Leibnitz Prize

DFG selects 10 researchers to receive 2015 Heinz Maier-Leibnitz Prize

This year's recipients of the most important prize for early career researchers in Germany have been announced. The selection committee, appointed by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the German Federal Ministry of Education and Research (BMBF), has chosen ten researchers, five women and five men, to receive the 2015 Heinz Maier-Leibnitz Prizes. [More]
Advertisement